Skip to main content
Figure 5 | EJNMMI Research

Figure 5

From: In vitro and in vivo pre-clinical analysis of a F(ab')2 fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers

Figure 5

Quantitation of tumor and normal organ distribution of 86 Y-CHX-A'-panitumumab F(ab') 2 . (a) Receptor-mediated uptake of 86Y-CHX-A"-panitumumab F(ab')2 of LS-174T tumor xenografts and normal organs 2 days post-injection of the RIC. Data represent the mean ± SEM from at least three determinations. (b) The specific activity of the 86Y- CHX-A"-panitumumab F(ab')2 was lowered by the addition of 15 μg of panitumumab F(ab')2. The mice were euthanized following the completion of the 48-h imaging session, the blood, tumor and normal organs were harvested and the radioactivity measured. (c) Comparison of the 48 h ex vivo quantitation at the two concentrations of panitumumab F(ab')2.

Back to article page